




# Annual Report for UTCoP Drug Discovery Center

Year 3: 7/1/2019-5/27/2020

Wei Li, Ph.D. on behalf of all DDC members



## UTCOP Drug Discovery Center Organization Structure



## UTCop DDC Advisory Committee

- **Dr. Richard Magid**, VP of UTRF
- **Dr. Gunda Georg**, Chair of Dept of Med Chem; Director of Institute for Therapeutics Discovery and Development (ITDD), University of Minnesota



# Accomplishment of the DDC in the year 3

- Current DDC members (7, in alphabetic order)

- Hevener, Kirk
- Jiang, Jianxiong
- Li, Wei
- Meibohm, Bernd
- Miller, Duane
- Palmer, Glen
- Yang, Chao-Yie



- Funding brought in during this year (continued and newly awarded)

- Total funding brought as PIs, Co-Is, or subcontractor PIs: \$9,277,382. Out of these:
- NEW awarded funding this year: \$2,519,132
- Amounts credited to UTCoP: \$4,033,320, **average per DDC member: \$576,189**
- **Contribute to UTCoP NIH ranking: \$3,509,365** (from various NIH institutions)

## Other Major Accomplishments

- Submitted a number of grant applications among DDC members
- At least one large center-like grant as PI (RM1GM139685-01), with requested amount of \$5.61M over five years was submitted and will be reviewed in July 2020.
- Anticipated the starting of a DoD grant (PI: Hevener) and an NCI R01 (PI: Li; Co-Is: Miller and Meibohom), both in July 1, 2020
- The two campus 2020 CORNET awards both involved with DDC members.
- A number of high-impact papers published by DDC members

## Plan for Year 4

- Work together to secure additional funding from various funding agencies, especially from the NIH which contributes to CoP's NIH ranking.
- Continue to publish high impact papers
- Have the 4<sup>nd</sup> meeting with Advisory Board members to report on progress and obtain advice for moving forward in May-June, 2021.
- Discuss with administrations on strategies to sustain the DDC operation after year 5.